Alcohol use and depression among African-American and Caucasian adolescents.

Autor: Maag JW (AUTHOR), Irvin DM (AUTHOR)

Publikováno v: Adolescence. Spring2005, Vol. 40 Issue 157, p87-101. 15p.

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.

Autor: Hariharan S; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Whitfield BT; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pirozzi CJ; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Pathology, Duke University Medical Center, Durham, NC, USA., Waitkus MS; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Brown MC; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Bowie ML; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Irvin DM; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Roso K; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Pathology, Duke University Medical Center, Durham, NC, USA., Fuller R; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Hostettler J; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Dharmaiah S; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gibson EA; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Briley A; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Mangoli A; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Fraley C; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Shobande M; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Stevenson K; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Molecular Physiology Institute, Duke University Medical Center, Durham, NC, USA., Zhang G; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Malgulwar PB; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Roberts H; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Roskoski M; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Spasojevic I; PK/PD Core Laboratory, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.; Department of Medicine - Oncology, Duke University Medical Center, Durham, NC, USA., Keir ST; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., He Y; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Pathology, Duke University Medical Center, Durham, NC, USA., Castro MG; Department of Neurosurgery, University of Michigan Medical Center, Ann Arbor, MI, USA., Huse JT; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jhuse@mdanderson.org., Ashley DM; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA. david.ashley@duke.edu.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA. david.ashley@duke.edu.

Publikováno v: Nature communications [Nat Commun] 2024 Jan 25; Vol. 15 (1), pp. 730. Date of Electronic Publication: 2024 Jan 25.

Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection.

Autor: Okolie O; Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Irvin DM; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Division of Neuropathology, Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Department of Neurology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Neuroscience Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Bago JR; Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Sheets K; Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Satterlee A; Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Carey-Ewend AG; Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Lettry V; Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Dumitru R; UNC Human Pluripotent Stem Cell Core, Genetics Department, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Elton S; Department of Neurosurgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Ewend MG; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Department of Neurosurgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Miller CR; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Division of Neuropathology, Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Department of Neurology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Neuroscience Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; UNC Neuroscience Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Hingtgen SD; Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Department of Neurosurgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; UNC Neuroscience Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

Publikováno v: PloS one [PLoS One] 2018 Jul 10; Vol. 13 (7), pp. e0198596. Date of Electronic Publication: 2018 Jul 10 (Print Publication: 2018).

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

Autor: McNeill RS; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Canoutas DA; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Stuhlmiller TJ; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Dhruv HD; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Irvin DM; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Bash RE; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Angus SP; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Herring LE; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Simon JM; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Skinner KR; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Limas JC; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Chen X; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Schmid RS; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Siegel MB; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Van Swearingen AED; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Hadler MJ; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Sulman EP; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Sarkaria JN; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Anders CK; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Graves LM; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Berens ME; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Johnson GL; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas., Miller CR; Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Publikováno v: Neuro-oncology [Neuro Oncol] 2017 Oct 19; Vol. 19 (11), pp. 1469-1480.

Intrinsic Astrocyte Heterogeneity Influences Tumor Growth in Glioma Mouse Models.

Autor: Irvin DM; Curriculum in Genetics and Molecular Biology, University of North Carolina School of Medicine, Chapel Hill, NC., McNeill RS; Pathobiology and Translational Science Graduate Program, University of North Carolina School of Medicine, Chapel Hill, NC.; Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC., Bash RE; Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC., Miller CR; Curriculum in Genetics and Molecular Biology, University of North Carolina School of Medicine, Chapel Hill, NC.; Pathobiology and Translational Science Graduate Program, University of North Carolina School of Medicine, Chapel Hill, NC.; Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC.; Department of Neurology and Neurosciences Center, University of North Carolina School of Medicine, Chapel Hill, NC.

Publikováno v: Brain pathology (Zurich, Switzerland) [Brain Pathol] 2017 Jan; Vol. 27 (1), pp. 36-50. Date of Electronic Publication: 2016 Apr 13.